Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IZTCNASDAQ:OCXNASDAQ:PYXSOTCMKTS:TRXDW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIZTCInvizyne Technologies$12.81-2.6%$12.59$8.50▼$23.00$80.09MN/A37,647 shs166 shsOCXOncoCyte$2.65-1.9%$2.97$1.92▼$4.75$75.79M0.9758,890 shs17,561 shsPYXSPyxis Oncology$1.20-1.6%$1.13$0.83▼$5.39$74.34M1.18744,937 shs347,399 shsTRXDWTransEnterix$0.15$0.15$0.12▼$0.18$21.42M2.568,250 shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIZTCInvizyne Technologies-2.59%-4.66%-11.96%-16.55%+1,280,999,900.00%OCXOncoCyte0.00%-10.77%-5.02%-29.14%-3.64%PYXSPyxis Oncology0.00%-11.11%+8.11%+8.11%-68.83%TRXDWTransEnterix0.00%0.00%0.00%0.00%+13,536.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AOCXOncoCyte2.801 of 5 stars3.44.00.00.03.30.80.6PYXSPyxis Oncology2.2387 of 5 stars3.42.00.00.03.30.80.6TRXDWTransEnterixN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIZTCInvizyne Technologies 0.00N/AN/AN/AOCXOncoCyte 2.75Moderate Buy$6.06128.77% UpsidePYXSPyxis Oncology 2.80Moderate Buy$9.00650.00% UpsideTRXDWTransEnterix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TRXDW, OCX, IZTC, and PYXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025OCXOncoCyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.005/21/2025OCXOncoCyteLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.005/19/2025PYXSPyxis OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/13/2025OCXOncoCyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.25 ➝ $4.254/8/2025OCXOncoCyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.25 ➝ $4.253/28/2025OCXOncoCyteLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.003/25/2025OCXOncoCyteStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight ➝ Equal Weight$4.00 ➝ $4.003/25/2025OCXOncoCyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.25 ➝ $4.253/19/2025PYXSPyxis OncologyRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.003/19/2025PYXSPyxis OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AOCXOncoCyte$3.84M19.72N/AN/A$2.48 per share1.07PYXSPyxis Oncology$16.15M4.60N/AN/A$2.81 per share0.43TRXDWTransEnterix$8.53M2.51$0.11 per share1.40$2.68 per share0.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIZTCInvizyne TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AOCXOncoCyte-$27.78M-$3.53N/AN/AN/A-6,122.29%-269.32%-59.71%8/6/2025 (Estimated)PYXSPyxis Oncology-$73.79M-$1.59N/AN/AN/AN/A-36.22%-28.76%8/13/2025 (Estimated)TRXDWTransEnterix-$154.20M-$4.22N/AN/AN/A-2,149.15%-83.74%-64.94%N/ALatest TRXDW, OCX, IZTC, and PYXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PYXSPyxis Oncology-$0.29-$0.35-$0.06-$0.35N/AN/A5/12/2025Q1 2025OCXOncoCyte-$0.24-$0.26-$0.02-$0.26$0.13 million$2.14 million3/24/2025Q4 2024OCXOncoCyte-$0.40$0.48+$0.88-$1.93$0.16 million$1.49 million3/18/2025Q4 2024PYXSPyxis Oncology-$0.33-$0.32+$0.01-$0.60N/A$16.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AOCXOncoCyteN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/ATRXDWTransEnterixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIZTCInvizyne TechnologiesN/AN/AN/AOCXOncoCyteN/A0.530.50PYXSPyxis OncologyN/A7.337.33TRXDWTransEnterix0.043.242.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIZTCInvizyne TechnologiesN/AOCXOncoCyte55.35%PYXSPyxis Oncology39.09%TRXDWTransEnterix8.22%Insider OwnershipCompanyInsider OwnershipIZTCInvizyne TechnologiesN/AOCXOncoCyte2.05%PYXSPyxis Oncology10.60%TRXDWTransEnterix3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIZTCInvizyne Technologies296.25 millionN/AN/AOCXOncoCyte12028.60 million17.18 millionNo DataPYXSPyxis Oncology6061.95 million53.64 millionOptionableTRXDWTransEnterixN/A142.78 millionN/ANot OptionableTRXDW, OCX, IZTC, and PYXS HeadlinesRecent News About These CompaniesLife Science Partners L P Synergy's Net WorthFebruary 9, 2024 | benzinga.comAsensus Surgical Inc (ASXC)January 30, 2024 | investing.comTransEnterix, Inc. (TRXDW)January 21, 2024 | ca.finance.yahoo.comSurgical Robots Global Market Report 2023June 13, 2023 | finance.yahoo.comAsensus Surgical (NYSEMKT: ASXC)May 27, 2023 | fool.comProfitable Strategic Report for the Robotic Endoscopy Devices Market with Business Strategies, Current Insight - openPRMay 12, 2023 | news.google.comAsia Pacific Minimally Invasive Gastrointestinal (GI) Surgical ... - Cottonwood Holladay JournalMay 12, 2023 | news.google.comGlobal Minimally Invasive Gastrointestinal (GI) Surgical Systems ... - Cottonwood Holladay JournalMay 12, 2023 | news.google.comAsensus Surgical, Inc. Reports Operating and Financial Results for ... - BenzingaMay 12, 2023 | news.google.comSurgical Robots Market 2023 is Booming Across the Globe by ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comBariatric Surgery Devices Market Size, Trends, Share, Growth and ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comSurgical Robots Market: The global market is expected to grow at a ... - Digital JournalMay 10, 2023 | news.google.comMinimally Invasive Gastrointestinal (GI) Surgical Systems Market ... - Digital JournalMay 10, 2023 | news.google.comSurgical Robots Market to Grow at Rapid Pace with Advancements ... - Digital JournalMay 10, 2023 | news.google.comMedical Intelligent Auxiliary Robot Market 2023 Competitive Insights ... - Cottonwood Holladay JournalMay 10, 2023 | news.google.comGlobal Healthcare Robotics-Surgical Robots Market 2023, CAGR ... - Cottonwood Holladay JournalMay 9, 2023 | news.google.comSurgical Robots Market Excellent CAGR of 18%, Growth, Industry ... - Digital JournalMay 8, 2023 | news.google.comExponential Growth Expected for Intelligent Tissue Autonomous Robots Market With Complete SWOT Analysis by For - openPRMay 8, 2023 | news.google.comObesity Surgery Device Market Research Report 2023-2031 Market ... - The Northwestern ExaminerMay 7, 2023 | news.google.comGlobal Surgical Robotics Market Insights Report 2022, Trends ... - FylladeyMay 5, 2023 | news.google.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRXDW, OCX, IZTC, and PYXS Company DescriptionsInvizyne Technologies NASDAQ:IZTC$12.81 -0.34 (-2.59%) As of 06/13/2025Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.OncoCyte NASDAQ:OCX$2.65 -0.05 (-1.85%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.71 +0.06 (+2.26%) As of 06/13/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Pyxis Oncology NASDAQ:PYXS$1.20 -0.02 (-1.64%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.20 0.00 (0.00%) As of 06/13/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.TransEnterix OTCMKTS:TRXDW$0.15 0.00 (0.00%) As of 03/7/2025TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
